Terns Pharmaceuticals Inc (NASDAQ:TERN) — Market Cap & Net Worth
Market Cap & Net Worth: Terns Pharmaceuticals Inc (TERN)
Terns Pharmaceuticals Inc (NASDAQ:TERN) has a market capitalization of $87.01 Million ($87.01 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19786 globally and #4512 in its home market, demonstrating a 63.27% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Terns Pharmaceuticals Inc's stock price $0.80 by its total outstanding shares 108767281 (108.77 Million). Also see Terns Pharmaceuticals Inc balance sheet assets for a full breakdown of the balance sheet.
Terns Pharmaceuticals Inc Market Cap History: 2021 to 2026
Terns Pharmaceuticals Inc's market capitalization history from 2021 to 2026. Data shows change from $768.98 Million to $87.01 Million (-44.81% CAGR). Also see Terns Pharmaceuticals Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Terns Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #559 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1905 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.00% | #241 of 263 |
Weight: Terns Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Terns Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Terns Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check TERN stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
768.98x
Terns Pharmaceuticals Inc's market cap is 768.98 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $768.98 Million | $1.00 Million | -$50.16 Million | 768.98x | N/A |
Competitor Companies of TERN by Market Capitalization
Companies near Terns Pharmaceuticals Inc in the global market cap rankings as of September 17, 2026. Review Terns Pharmaceuticals Inc tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Terns Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Terns Pharmaceuticals Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Terns Pharmaceuticals Inc's market cap moved from $768.98 Million to $ 87.01 Million, with a yearly change of -44.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $87.01 Million | -98.02% |
| 2025 | $4.39 Billion | +629.24% |
| 2024 | $602.57 Million | -14.64% |
| 2023 | $705.90 Million | -36.25% |
| 2022 | $1.11 Billion | +43.99% |
| 2021 | $768.98 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Terns Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $87.01 Million USD |
| MoneyControl | $87.01 Million USD |
| MarketWatch | $87.01 Million USD |
| marketcap.company | $87.01 Million USD |
| Reuters | $87.01 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Terns Pharmaceuticals Inc
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hor… Read more